On the heels of our report on concerns for increased risks of breast cancer from Hormone Replacement Therapy (HRT) comes new evidence that another option for treating menopausal symptoms, Livial (a synthetic hormone, with a generic formula known as Tibolone), may also raise the risk for breast cancer. Maybe hot flashes aren’t so bad after all. Many women who experience the very bothersome side effects of menopause are looking for options to help relieve their symptoms. However, over the last few weeks we have seen reports that are very disturbing regarding the chances of breast cancer being elevated in women who try to ward off menopausal symptoms. HRT, and now Livial, a synthetic steroid also used to treat menopausal symptoms, has been shown to significantly increase the odds of breast cancer recurrence. Researchers halted the study six months early due to the drastically increased risk of recurrent breast cancer found while studying women who were taking Tibolone. The recently released study (Lancet Oncology) involved 3,100 women who had undergone surgery for breast cancer prior to the study. The women were randomly divided into two groups with a placebo group and a Tibolone group, who were administered 2.5 milligrams of Tibolone daily.

Read the original here Another Menopausal Treatment Increases Risk of Cancer Recurreance